Join our daily newsletter At The Bell to receive exclusive market insights
- Respiri (RSH) has signed an agreement with TerryWhite Chemmart to sell and market its Wheezo product, commencing immediately
- Wheezo is an eHealth app that uses a handheld device to analyse breath sounds for wheeze, assisting asthma patients by tracking symptoms, triggers, and monitoring medication use
- With over 450 community pharmacies, Respiri says TerryWhite Chemmart pharmacies are well placed to offer the Wheezo product as an assistance for asthma management
- Respiri is also continuing discussions with several other large pharmacy banner groups, which will be announced once finalised and initial orders begin
- Respiri shares are up 13.6 per cent, trading at 12.5 cents
Respiri (RSH) has signed an agreement with Australia’s largest pharmacy network to sell and market its Wheezo product.
The eHealth company supporting respiratory health management, Respiri, has signed agreements with TerryWhite Chemmart, with sales of Wheezo to begin immediately.
Wheezo is an eHealth app that uses a handheld device to analyse breath sounds for wheeze, assisting asthma patients by tracking symptoms, triggers and monitoring medication use. The platform has been designed to make sharing information with doctors and health care professionals simple.
With over 450 community pharmacies, the company says TerryWhite Chemmart pharmacies are well placed to bring Wheezo to asthma patients and assist with the overall improvement of asthma management.
“Respiri continues to grow Wheezo product availability in the pharmacy channel as we recognise the important role that pharmacies play with supporting asthma management and care,” said Respiri CEO and Managing Director, Marjan Mikel.
“This agreement with Terry White Chemmart takes the number of pharmacies contracted to stock and sell Wheezo to approximately 1,000 stores, representing an implied market footprint of 22 per cent, based on the total number of ex-hospital community pharmacies across the country.”
Respiri is also continuing discussions with several other large pharmacy banner groups, which will be announced once finalised and initial orders begin.
Respiri shares are up 13.6 per cent, trading at 12.5 cents at 12:30 pm AEST.
